natgillin/translations-raw huggingface dataset:
Numerous chemotherapeutic protocols will present themselves in the mind of the skilled practitioner as being capable of incorporation into the method of the invention. 
Metoda pravljenja antitijela ili njegovog antigen-vezujućeg fragmenta iz zahtjeva 1, naznačena time, što sadrži eksprimiranje spomenutog antitijela u stanici-domaćinu.
Use of a compound having the structure shown in claim 1 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a disease or disorder selected from multiple myeloma, glioblastoma, and lymphoma. 
Uporaba spoja prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju lijeka za liječenje bolesti ili poremećaja povezanih sa nekontroliranim, nenormalnim i/ili neželjenim staničnim djelovanjima.
A host cell comprising one or more cloning or expression vectors according to claim 14. A process for the production of the antibody of any one of claims 1 to 11, comprising culturing the host cell of claim 15 and isolating the antibody. 
Postupak za proizvodnju humaniziranog antitijela koji obuhvaća uzgoj u kulturi stanice domaćina prema zahtjevu 8 pod uvjetima koji podržavaju ekspresiju humaniziranog antitijela koje vezuje VLQELNVTV (SEQ ID NO: 45) kada se veže za HLA-A2 receptor.
Therefore, in some aspects the oligomeric compound comprises at least two phosphodiester groups, wherein at least one is as according to the above statement of invention, and the other is positioned between the second and third regions, optionally between a linker group and the second region. 
Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 15, naznačen time, da kovalentna poveznica između druge i treće regije obuhvaća skupinu odabranu od fosfodiestera, fosforotioata te fosforoditioata ili boranofosfatne skupine, poput fosfodiesterske skupine.
The system of claim 1 wherein the drive means are further configured to provide a drive signal such that the first frequency and the second frequency overlap. 
Sustav u skladu sa zahtjevom 1, naznačen time, da su upravljačka sredstva nadalje podešena da prenose upravljački signal tako da se prva frekvencija i druga frekvencija preklapaju.
Multi-purpose truck for re-establishment of safe and practicable road conditions after car accidents, through cleaning of the road platform 
VIÅ ENAMJENSKI KAMION ZA PONOVNO USPOSTAVLJANJE SIGURNIH I PROHODNIH UVJETA NA CESTI NAKON AUTOMOBILSKIH NEZGODA, ČISĆENJEM CESTOVNE PLOHE
mediates T cell proliferation; or 
(C) posreduje proliferaciju T stanica; ili
A compound of any of claims 1-5 or a pharmaceutically acceptable salt thereof for use in medicine. 
Spoj prema zahtjevu 1, zahtjevu 2 ili zahtjevu 3 za uporabu u medicini.
Inhibition of VEGF correlates with inhibition of ErbB3 phosphorylation (FIG. 
(vii) inhibicija sferoidnog rasta stanica koje eksprimiraju ErbB3;
The combination of claim 6 wherein one of the active ingredients is selected from the group consisting ofTruvada, Viread, Emtriva, d4T, Sustiva, or Amprenavir antiviral compounds. 
Kombinacija prema zahtjevu 5, pri čemu je jedan od aktivnih sastojaka odabran iz grupe koja se sastoji od Tenofovir Disoproksila (Viread), Emtricitabina (Emtriva), kombinacije Tenofovira i Emtricitabina (Truvada), d4T, Efavirenza (Sustiva) ili Amprenavir antivirusnih spojeva.
A compound of formula (I), or salt thereof, wherein: 
Spoj s formulom (1), ili njegova sol, naznačen time da:
obtaining the DNA from said sample; amplifying the nucleic acid sequence corresponding to a specific region of the EGFR gene by means of PCR using a Protein-Nucleic Acid probe; and 
(ii) amplifikaciji slijeda nukleinske kiseline koji odgovara specifičnoj regiji EGER gena PCR-om pomoću proteinsko-nukleinskokiselinske sonde, gdje navedena proteinsko-nukleinskokiselinska sonda može specifično prepoznati i hibridizirati sa slijedom EGFR-a divljeg tipa, inhibirajući tako njegovu amplifikaciju; i
wherein A, B, C, and D are independently selected from CR2 and N; wherein at least one of A, B, C, and D is CR2; wherein R2 is a member selected from H, alkyl, heteroalkyl, aryl, halogen, arylalkyl, R6O-, and R6S-, wherein R6 is alkyl; wherein when two adjacent of A, B, C, and D are CR2, the two R2's may combine to form a single aryl, cycloalkyl, or heterocycloalkyl group; 
O O gdje su A, B, C 1 D nezavisno izabrani od CR, i N; gdje je najmanje jedan od A, B, Ci D jednak CR;; gdje je R; izabran od H, alkil, heteroalkil, aril, arilalkil, halogen grupe; i gdje kada su dva susjedna od A, B, CiD jednaka CR;, dva R; mogu se spojiti tako da formiraju jednu aril, cikloalkil ili heterocikloalkil grupu;
The locking nail system according to any of claims one to nine, which system further comprises one or more of the following elements: bit, depth gauge, cannulated screwdriver, diapason impactor, bit with limiter and reference guide-pin. 
Sustav čavla sa zaključavanjem prema bilo kojem od zahtjeva 1 do 7, pri čemu isti dodatno obuhvaća jedan ili više sljedećih elemenata: svrdlo, mjerilo dubine, kanulirani odvijač, udarač, svrdlo s graničnikom i referentni zatik za vođenje.
reacting the compound of the Formula VII with a suitable chlorinating agent in the presence of a suitable base and a suitable solvent selected from toluene and anisole, wherein the reaction is carried out by: 
(g) reakciju spoja formule VII sa prikladnim agensom za kloriranje u prisutnosti prikladne baze i prikladnog otapala, gdje se reakcija provodi uz:
The phakic posterior chamber intraocular lens of Claim 6, wherein the crosslinking agent comprises 0.2 to 1.0 wt. % allyl methacrylate. 
Fakična intraokularna leća za stražnju očnu komoru u skladu s patentnim zahtjevom 6, naznačena time što sredstvo za umrežavanje sadrži 0,2 do 1,0%, težinski, alil-metakrilata.
The composition or vaccine of claim 5, wherein the expression of the first heterologous polynucleotide coding for and expressing an NDV-F antigen is regulated by the SV40 promoter having the sequence as set forth in SEQ ID NO: 9. 
Sastav ili cjepivo za uporabu prema zahtjevima 1-2, naznačen/o time, da polinukleotid koji kodira NDV-F ima najmanje 90% identiteta sekvence prema SEQ ID NO: 1, 8, 49, 51 ili 53.
a pressurized metered dose inhaler or a aqueous/ethanolic droplet inhaler comprising the RESPIMAT® inhaler or another inhalation device using the RESPIMAT® aerosol-generating technology; and 
inhalator s mjernom dozom pod pritiskom ili vodeno/etanolni kapljični inhalator kao što je Respimat® inhalator ili drugi inhalacijski uređaj koji koristi Respimat® tehnologiju za generiranje aerosola, i
The antisense oligonucleotide of claim 1, wherein the inter-nucleotide linkages of the oligonucleotide backbone are replaced with non-natural inter-nucleotide linkages. 
Antisens oligonukleotid u skladu sa zahtjevom 1, naznačen time što internukleotidne veze u oligonukleotidnoj okosnici su zamijenjene neprirodnim internukleotidnim vezama.
A compound according to claim 1, wherein R3 is selected from the group consisting of C1-10-alk(enlyn)yl, Ar-C1-6-alk(en/yn)yl and Ar. 
Spoj prema patentnom zahtjevu 1, naznačen time što je R3 izabran iz grupe koju čine C,.,g-alk(en/in)il, Ar-C,.6- alk(en/in)il i Ar.
According to another embodiment the calcium carbonate has a particle size from 0.1 to 100 µm, from 0.5 to 50 µm, from 1 to 15 µm, preferably from 2 to 10 µm, most preferably 3 to 5 µm. 
Postupak prema bilo kojem od prethodnih zahtjeva, pri čemu kalcij karbonat ima veličinu čestica od 0.5 do 50 um, od 1 do 15 um, poželjno od 2 do 10 um, najpoželjnije 3 do 5 um.
RI is an alkyl, alkenyl or alkynyl having 1-18 carbon atoms; R is H or a tertiary alkyl group of formula (II): 
R' je alkil, alkenil ili alkinil koji ima 1-18 ugljikovih atoma; R je H ili tercijarna alkilna skupina formule (II):
reaction of C with phenyl fluorenyl bromide to create compound 3 . 
(c) reakciju C s fenil fluorenil bromidom kako bi se dobio spoj 3 ili s benzil bromidom kako bi se dobio spoj So kk pa A
A kit, comprising: a container that contains a pharmaceutical composition containing a peptide according to any one of claims 1 to 4, the nucleic acid or the expression vector according to claim 5, a cell according to claim 7, or an activated cytotoxic T lymphocyte produced according to claim 9, in solution or in lyophilized form; 
(a) posudu koja sadrži farmaceutski sastav koji sadrži peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, nukleinskom kiselinom ili vektorom ekspresije u skladu s patentnim zahtjevom 4, stanicom u skladu s patentnim zahtjevom 6 ili aktiviranim citotoksičnim T limfocitom u skladu s patentnim zahtjevom 8, u otopini ili u liofiliziranom obliku;
Fig. 5 shows cross-section B-B of fig. 2, wherein the detachable wall member 21 defines channels 23 for fluid and/or instruments. The second guiding passage 11 is shown. 
Slika 5 prikazuje poprečni presjek B - B 1z slike 2, pri čemu element stijenke 21, koji se može odvojiti, definira kanale 23 za fluid i/ili kanale za instrumente.
In a further embodiment compound (VII) is provided; n-butyl lithium in THF as well as DMF as formylating agent are added in order to perform a one-pot reaction. 
U sljedećoj izvedbi koristi se spoj (VII); dodaju mu se n-butil-litij u THF, kao i DMF kao formilirajući agens, da bi se izvela reakcija u istoj reakcijskoj posudi.
obtaining an effective coefficient flag of a sub residual block among the sub residual blocks from a bitstream, the effective coefficient flag of the sub residual block indicating whether at least one non-zero effective transformation coefficient exists in the sub residual block; when the effective coefficient flag indicates that at least one non-zero transformation coefficient exists in the sub residual block, obtaining transformation coefficients of the sub residual block based on location information of the non-zero transformation coefficient and level information of the non-zero transformation coefficient obtained from the bitstream; and 
kada zastavica kodiranog bloka označava da rezidualni blok transformacije sadrži barem jedan efektivni koeficijent transformacije koji nije nula, dobivanje koeficijenata transformacije prve jedinice frekvencijskog pojasa na temelju karte značajnosti koja ukazuje na mjesta efektivnih koeficijenata transformacije koji nisu nula koji postoje u prvoj jedinici frekvencijskog pojasa i informacije o razini efektivnih koeficijenata transformacije koji nisu nula koji postoje u prvoj jedinici frekvencijskog pojasa dobivenoj iz toka bitova;
the treatment of pain, irrespective of its origin, such as post-operative pain, neuromuscular pain, headaches, cancer-related pain, dental pain or osteoarticular pain; 
– liječenja boli, bez obzira na njeno podrijetlo, poput postoperativne boli, neuromuskularne boli, glavobolja, boli povezane s rakom, zubobolje ili osteoartikularne boli;
According to one embodiment of the present process, the at least one dispersing agent is added exclusively during step e). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se najmanje jedno dispergirajuće sredstvo dodaje isključivo tijekom koraka e).
the substituent group D is selected from the group consisting of halogen, cyano, hydroxy, carboxy, formyl, amino, oxo, nitro, lower alkyl, halogeno lower alkyl, lower alkyloxy, carbocycle lower alkyloxy, heterocycle lower alkyloxy, halogeno lower alkyloxy, lower alkyloxy lower alkyl, lower alkyloxy lower alkyloxy, lower alkylcarbonyl, lower alkyloxycarbonyl, lower alkylamino, lower alkylcarbonylamino, lower alkyl aminocarbonyl, lower alkylsulfonyl, lower alkylsulfonylamino, carbocyclic group optionally substituted by substituent group C, heterocyclic group optionally substituted by substituent group C, carbocycle lower alkyl optionally substituted by substituent group C, and heterocycle lower alkyl optionally substituted by substituent group C. 
Supstituentska skupina D: halogen, cijano, hidroksi, karboksi, formil, amino, okso, nitro, niži alkil, halogeno niži alkil, niži alkiloksi, karbociklil-niži alkiloksi, heterociklil-niži alkiloksi, halogeno niži alkiloksi, niži alkiloksi-niži alkil, niži alkiloksi-niži alkiloksi, niži alkilkarbonil, niži alkiloksikarbonil, niži alkilamino, niži alkilkarbonilamino, niži alkilaminokarbonil, niži alkilsulfonil, niži alkilsulfonilamino, karbociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, heterociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, karbociklil-niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, i heterociklil-niži alkil prema potrebi supstituiran sa supstituentskom skupinom C;
Number of cells analyzed 
Broj međunarodne objave:
These and other modifications, which will be apparent to those skilled in the art, should be considered within the scope of the following claims. 
Ove i druge modifikacije, što je očito stručnjacima u ovom području, se trebaju razmatrati unutar opsega sljedećih patentnih zahtjeva.
In both these report the fatty acid is incorporated in the resin prior to application and not used as diluent in the system. 
U ta dva izvještaja masna kiselina se ugrađuje u smolu prije nanošenja i ona se u sistemu ne upotrebljava kao sredstvo za razrjeđivanje.
a protein-binding segment that interacts with the chimeric Cas9 protein, wherein the protein-binding segment comprises two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex, wherein (a) and (b) are in the same or separate containers. 
(ii) segment koji veže protein 1 koji međudjeluje s kimernim proteinom Cas9, pri čemu segment koji veže protein, obuhvaća dva komplementarna odsjeka nukleotida koji hibridiziranju za tvorbu dvostruke RNK strukture (AsRNK)-dupleks, te time, da su (a) i (b) u zajedničkom spremniku ili u odvojenim spremnicima.
The compound of claim 4, wherein: 
Spoj prema zahtjevu 4, pri čemu:
A compound according to claim 1, wherein R1 is substituted phenyl, substituted phenyl-C1-12-alkyl, substituted phenylalkenyl, substituted naphthyl, substituted indolyl, substituted quinolyl, or substituted isoquinolyl, wherein substituted phenyl, substituted phenyl-C1-12-alkyl, substituted phenylalkenyl, substituted naphthyl, substituted indolyl, substituted quinolyl and substituted isoquinolyl are substituted with R7, R8 and R9. 
Spoj prema patentnom zahtjevu 1, naznačen time, da je R1 supstituirani fenil, supstituirani fenil-C1−12−alkil, supstituirani fenilalkenil, supstituirani naftil, supstituirani indolil, supstituirani kinolil ili supstituirani izokinolil, pri čemu su supstituirani fenil, supstituirani fenil-C1−12−alkil, supstituirani fenilalkenil, supstituirani naftil, supstituirani indolil, supstituirani kinolil i supstituirani izokinolil, supstituirani s R7, R8 i R9.
pouring the mixture into a mold, 
(c) ulijevanje mješavine u kalup,
Additionally, this leaves the upper end of the generally cylindrical collapsible container opposing the outlet end to be shaped in a manner for optimal collapsing performance. 
K tome, to ostavlja mogućnost da se gornji kraj općenito cilindričnog sklopivog spremnika oblikuje nasuprot izlaznog kraja na način koji omogućuje optimalno sklopivo ponašanje.
For each vial the composition of the bulk solution was as follows (Table VIII), noting that the water evaporates during the freeze-drying procedure: 
Za svaku ampulu sastav otopina za punjenje bio je sljedeći (Tablica VIII), uz napomenu da voda isparava tokom procedure sušenja zamrzavanjem.:
Administration may be topical, parenteral, intravenous, intra-arterial, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, by suppositories, or oral administration. 
Farmaceutski pripravak prema zahtjevu 3 ili 4, naznačen time da je navedeni farmaceutski pripravak formuliran za lokalno, parenteralno, intravensko, intra-arterijsko, subkutano, intramuskularno, intrakranijalno, intraorbitalno, oftalmičko, intraventrikularno, intrakapsularno, intraspinalno, intracisternalno, intraperitonealno, intranazalno, putem aerosola, supozitorijama ili za oralno davanje.
The mixture was refluxed for 6 hours. 
Smjesu se refluksira 6 sati.
While an acrolein acetal is formed in Figure 35, it should be appreciated that other groups may be substituted for R13 and R14 of Scheme 9, such as those defined for the R8 and R9 groups exemplified in Figure 9, or others. 
Dok je akrolein acetal formiran na slici 35, trebalo bi uvažiti da druge skupine mogu biti supstituirane na Ris i Rua iz sheme 9, tako kao što su definirane za Rg i Ro skupine, navedene kao primjer na slici 9, ili druge.
The package according to claim 17, wherein the lactic acid bacteria are a combination of Lactobactllus brevis and Lactobacillus salivartus subs. 
Pakiranje u skladu s patentnim zahtjevom 17, naznačeno time što su mliječnokisele bakterije kombinacija vrsta Lactobacillus brevis 1 Lactobacillus salivartus subsp.
A tissue factor-bearing microvesicle as defined in claim 9 or a pharmaceutical composition as defined to any of claims 10 or 11 for use according to any of claims 14 or 15 wherein the tissue factor-bearing microvesicle or pharmaceutical composition is topically administered. 
Mikrovezikula koja nosi tkivni faktor kako je definirana u patentnom zahtjevu 9 ili farmaceutski sastav kako je definiran u bilo kojem od patentnih zahtjeva 10 ili 11 za uporabu u skladu s bilo kojim od patentnih zahtjeva 14 ili 15 pri čemu se mikrovezikula koja nosi tkivni faktor ili farmaceutski sastav primjenjuju topički.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, ipkonazola, protiokonazola, tebukonazola, epoksikonazola, propikonazola i kiprokonazola.
The amusement ride vehicle of claim 5 wherein the vehicle comprises outer sidewalls and a bottom surface and the plurality of recesses or the plurality of protrusions do not extend outward past the outer sidewalls or beneath the bottom surface of the vehicle body or above the top surface of the vehicle. 
pri čemu je mnoštvo izvora za raspršivanje vode smješteno tako da osigurava strujanje vode za udaranje u vozilo, naznačen time što vozilo ima donju površinu koja klizi po kliznoj površini i površine za udaranje vode (34) razmaknute na suprotnim stranama (16) tijela vozila; i pri čemu je mnoštvo izvora za raspršivanje vode prilagođenih tako da utječu na klizno gibanje vozila.
A variety of off-flavour generating reactions that are incited or accelerated by exposure to light have been described in the scientific literature. 
U znanstvenoj literaturi su opisane razne reakcije razvijanja ustajalog okusa, koje su potaknute ili ubrzane izlaganjem svjetlu.
The formulation according to item 6, wherein the rate-controlling agent is selected from the group comprising hydroxypropyl cellulose, hydroxypropyl methyl cellulose (HPMC), methyl cellulose, carboxymethyl cellulose and mixtures thereof. 
Formulacija prema zahtjevu 5, naznačena time, da sredstvo za kontrolu učestalosti je odabrano iz skupine koju čine hidroksipropilna celuloza, hidroksipropilna metilna celuloza (HPMC), metilna celuloza, karboksimetilna celuloza i njihove mješavine.
An orally disintegrating tablet (ODT) comprising less than or equal to 20 mg of a corticosteroid selected from the group consisting of fluticasone, flunisolide, ciclesonide, mometasone, beclomethasone and solvates and esters thereof, and at least one disintegrant, wherein the ODT disintegrates within 60 seconds in simulated saliva fluid when tested using the USP <701> Disintegration Test and is suitable for topical administration of the corticosteroid in the esophagus. 
Tableta za oralno disperziranje koja sadrži manje ili jednako 20 mg budezonida ili njegovog solvata ili estera i najmanje jedan farmaceutski prihvatljiv sastojak koji omogućuje razgradnju tablete u usnoj šupljini, naznačeno time da je tableta pogodna za topikalnu primjenu budezonida u gornjem gastrointestinalnom traktu.
titanium dioxide (TiO2) and zirconia (ZrO2), Alumina (Al2O3), lantania (La2O3), constitute a particularly useful group of fillers for use in the composite materials of the present invention. 
titanov dioksid (TiO,), cirkonijev oksid (ZrO>), auminijev oksid (AbO;), lantanov oksid (La203) čine posebno korisnu skupinu punila za upotrebu u kompozitnim materijalima iz izuma.
A compound according to any one of claims 1 to 6 for use in a method of treatment of a disorder or a disease mediated by aldosterone synthase, or responsive to the inhibition of aldosterone synthase activity. 
Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time, da se upotrebljava u postupku liječenja poremećaja ili bolesti posredovanog/e sa sintezom aldosterona, ili koji/koja reagira na inhibiciju djelovanja sinteze aldosterona.
Equisetum arvense in form of plant or part of plant, juice, dry extract, hydro alcoholic extract or glycolic extract 
- = Equisetum arvense u obliku biljke ili dijela biljke, soka, suhog ekstrakta, hidro alkoholnog ekstrakta ili glikolnog ekstrakta
<400> 23 A binding molecule capable of binding L1, being selected from the group consisting of single chain antibodies, scFv, multimers ofscFv like diabodies, triabodies or tetrabodies, antibody fragments, Fab, tandabs, flexibodies, bispecific antibodies, and chimeric antibodies, and/or 
Vežuća molekula koja se može vezati na LI, (a) koja se bira iz skupine koju čine jednolančana protutijela, scFv, multimeri scFv, poput diatijela, triatijela ili tetratijela, fragmenti protutijela, Fab, tandabs, fleksitijela, bispecifična protutijela, te kimerna protutijela, i/ili
The pharmaceutical composition of claim 8, the use of claim 9, 19 or 22 or the vaccine of claim 19 or 21, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, endometriosis, esophageal cancer, gastric cancer, diffused type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 8, upotreba u skladu s patentnim zahtjevom 9, 19 ili 22, ili cjepivo u skladu s patentnim zahtjevom 19 ili 21, naznačeni time što rak se bira iz skupine koju čine rak mokraćnog mjehura, rak dojke, rak vrata maternice, kolangiocelularni karcinom, CML, rak debelog crijeva, HR P20131044 T1 endometrioza, rak jednjaka, rak želuca, difuzni tip raka želuca, rak jetre, NSCLC, limfom, osteosarkom, rak jajnika, rak gušterače, rak prostate, karcinom bubrega, SCLC, tumor mekog tkiva i tumor testisa,
Compounds of the Examples herein below generally have IC50 values in the functional assay below 1 µM. 
Spojevi iz dolnjih primjera imaju općenito vrijednosti ICso u funkcionalnom pokusu ispod 1 uM.
wherein: VL1 is a first immunoglobulin light chain variable domain; 
VLi je varijabilna domena prvog lakog imunoglobulinskog lanca;
Figure 3 provides various dimensions, in millimeters, of a preferred embodiment. 
Slika 3 prikazuje razne dimenzije, u milimetrima, preferirane izvedbe.
The antibody or an antigen binding fragment thereof for the use of claim 8, wherein the human IgG4 constant region comprises the amino acid sequence of SEQ ID NO: 12, and the human k light chain constant region comprises the amino acid sequence of SEQ ID NO: 13. 
Protutijelo ili njegov ulomak koji veže antigen za uporabu prema zahtjevu 8, naznačen time što humana IgG4 konstantna regija sadrži aminokiselinsku sekvencu iz SEQ ID NO: 12, i humana x konstantna regija lakog lanca sadrži aminokiselinsku sekvencu iz SEQ ID NO: 13.